This podcast highlights the first regulatory approval for Casgevy, a gene therapy using CRISPR gene editing for sickle cell disease. Other breakthroughs in cell and gene therapy are discussed, including Verve 101 for cardiovascular disease, Axicab2Gin Silo-Lucial for lymphoma, Cascavii for sickle cell disease and beta thalassemia, AB 1002 for advanced heart failure, and global collaboration for CAR-T DDBCMA.
Verve Therapeutics's gene editing medicine, Verve 101, shows promise in lowering LDL-C cholesterol levels in patients with familial hypercholesterolemia.
Kite's CAR-T cell therapy, Axicabtagene Ciloleucel, significantly improves overall survival in patients with relapsed or refractory large B cell lymphoma.
Deep dives
Gene editing treatment shows promise in reducing cholesterol levels
A Phase 1B trial of Verve Therapeutics's Verve 101 showed significant reductions in LDL-C cholesterol levels and blood PCSK9 protein levels in patients with heterozygous familial hypercholesterolemia (HEFH). Verve 101 is an investigational gene editing medicine designed to inactivate the PCSK9 gene in the liver and durably lower LDL-C cholesterol levels. The trial data suggested successful editing in the intended genomic target, indicating the potential for single-course gene editing as a new approach for treating patients with HEFH.
CAR-T therapy improves survival in patients with large B cell lymphoma
Kite's CAR-T cell therapy, Axicabtagene Ciloleucel, has shown a 38% improvement in overall survival and a 27.4% reduction in the risk of death in patients with relapsed or refractory large B cell lymphoma (LBCL). The Phase 3 Zuma 7 study compared Axicabtagene Ciloleucel with standard of care (SOC) as an initial treatment for patients with LBCL. This therapy is the first to significantly improve survival in nearly 30 years for patients with relapsed or refractory LBCL.
World's first gene therapy for sickle cell disease and beta thalassemia authorized
The MHRA has authorized Cascaveli (Crispr Therapeutics and Vertex's gene therapy) for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). Cascaveli is a CRISPR-based therapy that edits the faulty gene in a patient's bone marrow stem cells to restore healthy hemoglobin production. Clinical trial data showed that the majority of patients with SCD and TDT experienced a reduction in severe pain crisis and a decreased need for red blood cell transfusions. This represents the first regulatory authorization of a CRISPR-based therapy in the world.
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.
The breaking news this week was certainly the first regulatory approval for Casgevy, not only the first gene therapy approved for sickle cell disease, but also the first therapy to use CRISPR gene editing. However, there were a number of other breakthroughs announced in the cell and gene therapy field.